Search hospitals

>

Washington

>

Kennewick

Kadlec Clinic Hematology and Oncology

Claim this profile

Kennewick, Washington 99336

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Cancer

Conducts research for Lymphoma

327 reported clinical trials

9 medical researchers

Photo of Kadlec Clinic Hematology and Oncology in KennewickPhoto of Kadlec Clinic Hematology and Oncology in KennewickPhoto of Kadlec Clinic Hematology and Oncology in Kennewick

Summary

Kadlec Clinic Hematology and Oncology is a medical facility located in Kennewick, Washington. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Lymphoma and other specialties. Kadlec Clinic Hematology and Oncology is involved with conducting 327 clinical trials across 457 conditions. There are 9 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.

Area of expertise

1

Breast Cancer

Global Leader

Kadlec Clinic Hematology and Oncology has run 67 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
Stage IV
ER positive
2

Lung Cancer

Global Leader

Kadlec Clinic Hematology and Oncology has run 56 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Kadlec Clinic Hematology and Oncology

Breast Cancer

Lung Cancer

Prostate Cancer

Bladder Cancer

Ovarian Cancer

Breast cancer

Esophageal cancer

Multiple Myeloma

Bladder Carcinoma

Colorectal Cancer

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Kadlec Clinic Hematology and Oncology?

Where is Kadlec Clinic Hematology and Oncology located?

Who should I call to ask about financial aid or insurance network?

What insurance does Kadlec Clinic Hematology and Oncology accept?

What awards or recognition has Kadlec Clinic Hematology and Oncology received?